ISSN 2305-3127 (Print)   
ISSN 2664-3790 (Online)

 

Варіанти перебігу і ведення пацієнтів з персистентною фібриляцією передсердь

Я.В. Скибчик, К.О. Міхалєв, О.Й. Жарінов

Література

  1. Fibrylyatsiya i tripotinnya peredserdʹ / Za red. O.Y. Zharinova, V.O. Kutsya .– K.: Chetverta khvylya, 2022.– 248 s.
  2. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114(9):1453-68. doi: 10.1161/CIRCRESAHA.114.303211. PMID: 24763464.
  3. Berger WR, Meulendijks ER, Limpens J, et al. Persistent atrial fibrillation: A systematic review and meta-analysis of invasive strategies. Int J Cardiol. 2019;278:137-43. doi: 10.1016/j.ijcard.2018.11.127. Epub 2018 Nov 29. PMID: 30553497.
  4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-32 .
  5. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. EP Europace. 2018;20(1):e1-e160. doi: 10.1016/0735-1097(91)90592-w.
  6. Camm AJ, Naccarelli GV, Mittal S, et al. The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(19):1932-48. doi: 10.1016/j.jacc.2022.03.337. PMID: 35550691.
  7. Cochet H, Mouries A, Nivet H, et al. Age, atrial fibrillation, and structural heart disease are the main determinants of left atrial fibrosis detected by delayed-enhanced magnetic resonance imaging in a general cardiology population. J Cardiovasc Electrophysiol. 2015;26(5):484-92. doi: 10.1111/jce.12651. Epub 2015 Apr 22. PMID: 25727248.
  8. Deshmukh A, Barnard J, Sun H, et al. Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol. 2015;8(1):32-41. doi: 10.1161/CIRCEP.114.001632. Epub 2014 Dec 18. PMID: 25523945; PMCID: PMC433469.
  9. Fosbol EL, Holmes DN, Piccini JP, et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc. 2013;2(4):e000110. doi: 10.1161/JAHA.113.000110. PMID: 23868192; PMCID: PMC3828776.
  10. Goette A, Kalman J, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterization, and clinical implication. EP Europace. 2016;18(10):1455-90. doi: 10.1007/s10840-012-9727-9
  11. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-66. doi: 10.1056/NEJM199809033391003. PMID: 9725923.
  12. Heijman J, Hohnloser S, Camm J, et al. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. EP Europace. 2021;23(2): ii14–ii22, https://doi.org/10.1093/europace/euaa426.
  13. Hindricks G, Potpara Т, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373-498. doi: 10.1007/s12410-019-9520-6.
  14. Imberti JF, Ding WY, Kotalczyk A, et al. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart. 2021;107:1630-6.
  15. Kirchhof P, Camm AJ, Goette A, et al. EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29. PMID: 32865375.
  16. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events – European Registry in Atrial Fibrillation (PREFER in AF). EP Europace. 2014;16(1);6-14. https://doi.org/10.1093/europace/eut263
  17. Konrad T, Theis C, Mollnau H, Sonnenschein S, Ocete BQ, Bock K, Münzel T, Rostock T. Primary Persistent Atrial Fibrillation: A Distinct Arrhythmia Subentity of an Ablation Population. J Cardiovasc Electrophysiol. 2015;26(12):1289-94. doi: 10.1111/jce.12818. Epub 2015 Oct 12. PMID: 26303513.
  18. Kordík P, Křemen V, Lhotska L. The GAME Algorithm Applied to Complex Fractionated Atrial Electrograms Data Set. 1970;5164:859-68. doi: 10.1007/978-3-540-87559-8_89.
  19. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J Cardiovasc Electrophysiol. 2012;23(7):797-9. doi: 10.1111/j.1540-8167.2012.02341.x. Epub 2012 May 3. PMID: 22554187.
  20. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34(35):2731-8. doi: 10.1093/eurheartj/eht194. Epub 2013 Jun 11. PMID: 23761394.
  21. Kottkamp H, Bender R, Berg J. Catheter ablation of atrial fibrillation: how to modify the substrate? J Am Coll Cardiol. 2015;65(2):196-206. doi: 10.1016/j.jacc.2014.10.034. PMID: 25593061.
  22. Lim H, Denis A, Middeldorp M, et al. Persistent Atrial Fibrillation From the Onset: A Specific Subgroup of Patients With Biatrial Substrate Involvement and Poorer Clinical Outcome. JACC: Clinical Electrophysiology. 2016;2(2):129-39. doi: 10.1016/j.jacep.2016.02.010.
  23. Lo LW, Tai CT, Lin YJ, et al. Predicting factors for atrial fibrillation acute termination during catheter ablation procedures: implications for catheter ablation strategy and long-term outcome. Heart Rhythm. 2009;6(3):311-8. doi: 10.1016/j.hrthm.2008.11.013. Epub 2008 Nov 19. PMID: 19251203.
  24. Magnocavallo M, Parlavecchio A, Vetta G, et al. Catheter Ablation versus Medical Therapy of Atrial Fibrillation in Patients with Heart Failure: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022;11(19):5530. doi: 10.3390/jcm11195530. PMID: 36233407; PMCID: PMC9572511.
  25. Mark D.B, Anstrom K.J, Sheng S et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1275-85.
  26. Marrouche NF, Brachmann J, Andresen D et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-27.
  27. Martins RP. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation. 2014;129(14):1472-82.
  28. Mody BP, Raza A, Jacobson J, et al. Ablation of long-standing persistent atrial fibrillation. Ann Transl Med. 2017;5(15):305. doi: 10.21037/atm.2017.05.21. PMID: 28856145; PMCID: PMC5555980.
  29. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J. 1959;58(1):59-70. doi: 10.1016/0002-8703(59)90274-1.PMID: 13661062.
  30. Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33(15):1870-7. doi: 10.1093/eurheartj/ehs079. Epub 2012 Apr 16. PMID: 22507975.
  31. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335-45. doi: 10.1016/j.jacc.2014.02.555. Epub 2014 Mar 19. PMID: 24613319.
  32. Nattel S. Paroxysmal atrial fibrillation and pulmonary veins: relationships between clinical forms and automatic versus re-entrant mechanisms. Can J Cardiol. 2013;29(10):1147-9.
  33. Oliveira IM, Oliveira BD, et al. Fibrosis, myocardial crossings, disconnections, abrupt turns, and epicardial reflections: do they play an actual role in human permanent atrial fibrillation? A controlled necropsy study. Cardiovasc Pathol. 2013;22(1):65-9. doi: 10.1016/j.carpath.2012.06.001. Epub 2012 Aug 20. PMID: 22917538.
  34. Platonov PG, Mitrofanova LB, Orshanskaya V, et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol. 2011;58(21):2225-32. doi: 10.1016/j.jacc.2011.05.061. PMID: 22078429.
  35. Scherr D, Khairy P, Miyazaki S, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol. 2015;8(1):18-24. doi: 10.1161/CIRCEP.114.001943. Epub 2014 Dec 20. PMID: 25528745.
  36. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, et al. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis. 2005;48(3):153-68.
  37. Steffel J, Collins R, Matthias Antz, at al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021;23(10):1612-76. https://doi.org/10.1093/europace/euab065
  38. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET- AF trial. Eur Heart J. 2015;36:288-96.
  39. Um KJ, McIntyre WF, Healey JS, et al. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace. 2019;21(6):856-63. doi: 10.1093/europace/euy310.
  40. Verma A, Jiang CY, Betts TR, et al. STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812-22. doi: 10.1056/NEJMoa1408288. PMID: 25946280.
  41. Wei SK, Ruknudin AM, Shou M, et al. Muscarinic modulation of the sodium-calcium exchanger in heart failure. Circulation. 2007;115(10):1225-33. doi:10.1161/CIRCULATIONAHA.106.650416. Epub 2007 Mar 5. PMID: 17339552.
  42. Wijffels MC, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954-68.
  43. Zoni-Berisso M, Lercari Y, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. J. Clin. Epidemiol. 2014;(6):213–20.
[PDF] [Зміст журналу]  

 

 

Посттравматичний стресовий розлад у пацієнтів із серцево-судинною патологією

А.С. Солонович, О.С. Солонович, О.А. Єпанчінцева

Література

  1. Nakaz Ministerstva okhorony zdorovʺya Ukrayiny 23.02.2016 № 121. Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy. Reaktsiya na stres ta rozlady
  2. Abla M. Sibai, Fletcher A, Armenian HK. Variations in the impact of long-term wartime stressors on mortality among the middle-aged and older population in Beirut, Lebanon, 1983–1993. Amer J Epidemiol. 2001;154(2):128-37. https://doi.org/10.1093/aje/154.2.128.
  3. Ahmadi N, Hajsadeghi F, Mirshkarlo HB, Budoff M, Yehuda  R, Ebrahimi R. Post-traumatic stress disorder, coronary atherosclerosis, and mortality. Am J Cardiol. 2011;108:29-33. 
  4. Amadio P, Zarà M, Sandrini L, Ieraci A, Barbieri SS. Depression and cardiovascular disease: The Viewpoint of Platelets. International J Molecular Scien. 2020;21(20):7560. https://doi.org/10.3390/ijms21207560.
  5. Austin AW, Wissmann T, Von Kanel R. Stress and hemostasis: An update. Semin Thromb Hemost. 2013;39:902-12.
  6. Avaro A, Gerosa G, Caforio AL, et al. Posttraumatic stress disorder and depression in heart transplantation recipients: the relationship with outcome and adherence to medical treatment. Gen Hosp Psychiatry. 2011;33:1-7. 
  7. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. part II: neurochemistry, neurophysiology and neurocognition. World J. Biol. Psychiatry. 2017;183:162-214. doi:10.1080/15622975.2016.1190867.
  8. Bedi US, Arora R. Cardiovascular manifestations of posttraumatic stress disorder. J Natl Med Assoc. 2007;99:642-9.
  9. Beis D, von Kanel R, Heimgartner N, Zuccarella-Hackl C, Burkle A, Ehlert U, et al. The role of norepinephrine and alpha-adrenergic receptors in acute stress-induced changes in granulocytes and monocytes. Psychosom. Med. 2018;807: 649-58. doi:10.1097/PSY.0000000000000620. 
  10. Belkin MR, Schwartz TL. Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. Drugs Context. 2015;4:212286. doi: 10.7573/dic.212286.
  11. Breslau N, Davis GC, Schultz LR. Posttraumatic stress disorder and the incidence of nicotine, alcohol, and other drug disorders in persons who have experienced trauma. Arch Gen Psychiatry. 2003;60:289-94.
  12. Buckley TC, Kaloupek DG. A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med. 2001;63:585-94. 
  13. Burg MM, Brandt C, Buta E, Schwartz J, Bathulapalli H, Dziura J, Edmondson DE, Haskell S. Risk for incident hypertension associated with posttraumatic stress disorder in military veterans and the effect of posttraumatic stress disorder treatment. Psychosom Med. 2017;79(2):181-8. doi: 10.1097/PSY.0000000000000376. PMID: 27490852; PMCID: PMC5285494.
  14. Byrne CJ, Khurana S, Kumar A, Tai TC. Inflammatory signaling in hypertension: regulation of adrenal catecholamine biosynthesis. Front Endocrinol (Lausanne). 2018;9:343.
  15. doi: 10.3389/fendo.2018.00343. PMID: 30013513; PMCID: PMC6036303.
  16. Ceylan ME, Alpsan-Omay MH. Bleeding induced by SSRIs. Eur Psychiatry. 2005;20:570-1.
  17. Cleveland S, Reed K, Thomas JL, Ajijola OA, Ebrahimi R, Hsiai  T, Lazarov A, Montoya AK, Neria Y, Shimbo D, Wolitzky-Taylor K, Sumner JA. Key dimensions of post-traumatic stress disorder and endothelial dysfunction: a protocol for a mechanism-focused cohort study. BMJ Open. 2021;5;11(5):e043060. doi: 10.1136/bmjopen-2020-043060. PMID: 33952541; PMCID: PMC8103395.
  18. Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM. Neuropsychiatric consequences of lipophilic beta-blockers. Medicina (Kaunas). 2021;57(2):155. doi: 10.3390/medicina57020155. PMID: 33572109; PMCID: PMC7914867.
  19. Coughlin SS. Post-traumatic stress disorder and cardiovascular disease. Open Cardiovasc Med J. 2011;5:164-70. doi: 10.2174/1874192401105010164. Epub 2011 Jul 11. PMID: 21792377; PMCID: PMC3141329. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345-67.
  20. Dennis PA, Kimbrel NA, Sherwood A, Calhoun PS, Watkins  LL, Dennis MF, Beckham JC. Trauma and autonomic dysregulation: episodic-versus systemic-negative affect underlying cardiovascular risk in posttraumatic stress disorder. Psychosom Med. 2017;79(5):496-505. doi: 10.1097/PSY.0000000000000438. PMID: 28570433; PMCID: PMC5466498.
  21. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
  22. Edmondson D, von Känel R. Post-traumatic stress disorder and cardiovascular disease. Lancet Psychiatry. 2017;4(4):320-9. doi: 10.1016/S2215-0366(16)30377-7. Epub 2017 Jan 19. PMID: 28109646; PMCID: PMC5499153.
  23. Edmondson D. An enduring somatic threat model of posttraumatic stress disorder due to acute life-threatening medical events. Soc Personal Psychol Compass. 2014;8:118-34.
  24. Edmondson DE, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. Am Heart J. 2013;166:806-14. 
  25. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26:1033-1049.
  26. Fox KM. Current status: heart rate as a treatable risk factor. Eur Heart J. 2011;13(suppl C):C30-C6. 
  27. Gander ML, von Kanel R. Myocardial infarction and post-traumatic stress disorder: frequency, outcome, and atherosclerotic mechanisms. Eur J Cardiovasc Prev Rehabil. 2006;13:165-72.
  28. Giustino TF, Fitgerald PG, Maren S. Revisiting propranolol and PTSD: Memory erasure or extinction enhancement? Neurobiology of learning and memory. 2016;130:26-33. doi:10.1016/j.nlm.2016.01.009.
  29. Grenon SM, Owens CD, Alley H, Perez S, Whooley MA, Neylan TC, Aschbacher K, Gasper WJ, Hilton JF, Cohen BE. Posttraumatic stress disorder is associated with worse endothelial function among veterans. J Am Heart Assoc. 2016;5(3):e003010. doi: 10.1161/JAHA.115.003010. PMID: 27009621; PMCID: PMC4943274.
  30. Grenon SM, Chong K, Alley H, Nosova E, Gasper W, Hiramoto J, Boscardin WJ, Owens CD. Walking disability in patients with peripheral artery disease is associated with arterial endothelial function. J Vasc Surg. 2014;59(4):1025-34. doi: 10.1016/j.jvs.2013.10.084. Epub 2014 Jan 11. PMID: 24423479; PMCID: PMC3966931.
  31. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology. 2008;33:1305-12.
  32. Jansen JO, Lord JM, Thickett DR, Midwinter MJ, McAuley DF, Gao F. Clinical review: Statins and trauma--a systematic review. Crit Care. 2013;17(3):227. doi: 10.1186/cc12499. PMID: 23751018; PMCID: PMC3706835.
  33. Kang HK, Bullman TA, Taylor JW. Risk of selected cardiovascular diseases and posttraumatic stress disorder among former World War II prisoners of war. Annals Epidemiology. 2016;5(16):381-6. doi.org/10.1016/j.annepidem.2005.03.004.
  34. Karlovic D, Buljan D, Martinac M, et al. Serum lipid concentrations in Croatian veterans with post-traumatic stress disorder, post-traumatic stress disorder comorbid with major depressive disorder, or major depressive disorder. J Korean Med Sci. 2004;19:431-6.
  35. Khoury NM, Marvar PJ, Gillespie CF, et al. The reninangiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry. 2012;73(6):849-55.
  36. Koenen KC, Galea S. Post-traumatic stress disorder and chronic disease: open questions and future directions. Soc Psychiatry Psychiatr Epidemiol. 2015;50:511-3. 
  37. Koenen KC, Ratanatharathorn A, Ng L, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260-74. doi: 10.1017/S0033291717000708. Epub 2017 Apr 7. PMID: 28385165; PMCID: PMC6034513.
  38. Kronish IM, Cornelius T, Schwartz JE, et al. Posttraumatic Stress Disorder and Electronically Measured Medication Adherence After Suspected Acute Coronary Syndromes. Circulation. 2020;142(8):817-9. doi:10.1161/CIRCULATIONAHA.120.045714.
  39. Kronish IM, Edmondson D, Goldfinger J, et al. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke. 2012;43(8):2192-7. doi:10.1161/STROKEAHA.112.655209.
  40. Kronish IM, Edmondson D, Moise N, et al. Posttraumatic stress disorder in patients who rule out versus rule in for acute coronary syndrome. Gen Hosp Psychiatry. 2018;53:101-7. doi: 10.1016/j.genhosppsych.2018.02.007. Epub 2018 May 16. PMID: 29773309; PMCID: PMC6291417.
  41. Kronish IM, Moise N, Bleck R, et al. PTSD and aversive cognitive associations about aspirin in acute coronary syndrome patients. Am Psychosomatic Society; Savannah, GA: 2015.
  42. Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned and future directions. Prog Cardiovasc Dis. 2013;55(6):590-600. doi: 10.1016/j.pcad.2013.02.001. Epub 2013 Mar 23. PMID: 23621969; PMCID: PMC3639439.
  43. Lakusic N, Fuckar K, Mahovic D, et al. Characteristics of heart rate variability in war veterans with post-traumatic stress disorder after myocardial infarction. Mil Med. 2007;172:1190-3.
  44.  Letsas K, Korantzopoulos P, Pappas L, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109:116-7.
  45. Liberzon I, Abelson JL, Flagel SB, et al. Neuroendocrine and psychophysiologic Responses in PTSD: A Symptom Provocation Study. Neuropsychopharmacology. 1999;21(1):40-50. doi:10.1016/S0893-133X(98)001286. 
  46. Lima BB, Hammadah M, Wilmot K, et al. Posttraumatic stress disorder is associated with enhanced interleukin-6 response to mental stress in subjects with a recent myocardial infarction. Brain Behav Immun. 2019;75:26-33. doi: 10.1016/j.bbi.2018.08.015.
  47. Lok A, Frijling JL, van Zuiden M. Posttraumatic stress disorder: current insights in diagnostics, treatment and prevention. Ned Tijdschr Geneeskd. 2018;161:D1905.
  48. LoVecchio F, Riley B, Pizon A, et al. Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. J Emerg Med. 2008;34:77-8. 
  49. Moraru A, Proca E, Zavadovschi A, et al. Post-traumatic stress disorder and cardiovascular disease. Romanian Journal of Military Medicine. 2022;CXXV: 97-111. doi:10.55453/rjmm.2022.125.1.13. 
  50. Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev. 2012;32:301-15.
  51. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463-75. 
  52. Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6:469-80.
  53. Palmer MC. Treating comorbid posttraumatic stress disorder and cardiovascular disease. Current Psychiatry. 2017;16(8):38-42.
  54. Pan X, Kaminga AC, Wen SW, Liu A. Catecholamines in post-traumatic stress disorder: A systematic review and meta-analysis. Front Mol Neurosci. 2018;11:450. doi: 10.3389/fnmol.2018.00450. PMID: 30564100; PMCID: PMC6288600.
  55. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2:1002–12.
  56. Piccirillo G, Magrì D, Matera S, et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study. Eur Heart J. 2007;28:1344-50. 
  57. Pole N, Pole N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull. 2007;133:725-46. 
  58. Pope B, Wood S. Stress-induced inflammation as the «connexin» between post-traumatic stress disorder and cardiovascular disease. Brain, Behavior, and Immunity. 2019;82:3-5.doi: 10.1016/j.bbi.2019.08.182. 
  59. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371-3.
  60. Rasmusson AM, Schnurr PP, Zukowska Z, et al. Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome. Exp Biol Med (Maywood). 2010;235(10):1150-62. doi: 10.1258/ebm.2010.009334. PMID: 20881319.
  61. Robicsek O, Makhoul B, Klein E, et al. Hypercoagulation in Chronic Post-Traumatic Stress Disorder. Isr Med Assoc J. 2011;13:548-52.
  62. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit. 2001;23:435-40.
  63. Rosenbaum S, Stubbs B, Ward PB, et al. The prevalence and risk of metabolic syndrome and its components among people with posttraumatic stress disorder: a systematic review and meta-analysis. Metabolis. 2015;64:926-33.
  64. Rosman L, Lampert R, Ramsey CM, et al. Posttraumatic Stress Disorder and Risk for Early Incident Atrial Fibrillation: A Prospective Cohort Study of 1.1 Million Young Adults. J Am Heart Assoc. 2019;8(19):e013741. doi: 10.1161/JAHA.119.013741. Epub 2019 Sep 28. PMID: 31564191; PMCID: PMC6806049.
  65. Rozanski A, Blumenthal JA, Davidson KW, et al. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: The emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45:637-51. 
  66. Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology. 2011;36(1):1-18. doi: 10.1016/j.psyneuen.2010.10.001.
  67. Sala M, Lazzaretti M, De Vidovich G, et al. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis. 2009;3:29-43.
  68. Schrader C, Ross A. A review of PTSD and current treatment strategies. Mo Med. 2021;118(6):546-51. PMID: 34924624; PMCID: PMC8672952.
  69. Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008;46:71-3.
  70. Shemesh E, Yehuda R, Milo O, et al. Posttraumatic stress, nonadherence, and adverse outcome in survivors of a myocardial infarction. Psychosom Med. 2004;66:521-6.
  71. Shemesh E. A pilot study of posttraumatic stress and nonadherence in pediatric liver transplant recipients. Pediatrics. 2000;105(2):E29. doi:10.1542/peds.105.2.e29.
  72. Sun HJ, Wu ZY, Nie XW, et al. Role of endothelial dysfunction in cardiovascular diseases: The link between inflammation and hydrogen sulfide. Front Pharmacol. 2020;10:1568. doi: 10.3389/fphar.2019.01568. PMID: 32038245; PMCID: PMC6985156.
  73. Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4:101-5.
  74. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. doi: 10.1152/physrev.00033.2011. PMID: 23303913.
  75. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24:205-14.
  76. van der Kolk B. Posttraumatic stress disorder and the nature of trauma. Dialogues Clin Neurosci. 2000;2(1):7-22. doi:10.31887/DCNS.2000.2.1/bvdkolk.
  77.  von Kanel R, Orth-Gomer K. Autonomic function and prothrombotic activity in women after an acute coronary event. J Womens Health (Larchmt) 2008;17:1331-7. 
  78. Warne JP. Shaping the stress response: Interplay of palatable food choices, glucocorticoids, insulin and abdominal obesity. Mol Cell Endocrinol. 2009;300(1–2):137-46.
  79. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;16(3):291-308. doi: 10.5339/gcsp.2014.43. PMID: 25780786; PMCID: PMC4352682.
  80. Wilson PG, Thompson JC, Shridas P, et al. Serum amyloid A
  81. is an exchangeable apolipoprotein. Arterioscler Thromb
  82. Vasc Biol. 2018;38(8):1890-900. doi: 10.1161/ATVBAHA.118.310979.
  83. Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Ann NY Acad Sci. 2006;1071:137-66.
  84. Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013 28;8(4):169-76.
  85. Zen AL, Whooley MA, Zhao S, et al. Post-traumatic stress disorder is associated with poor health behaviors: Findings from the Heart and Soul Study. Health Psychol. 2012;31:194-201. 
[PDF] [Зміст журналу]  

 

 

Причини та фактори ризику розвитку рестенозу стента у хворих після черезшкірних коронарних втручань

М.П. Копиця, І.М. Кутя, Ю.В. Родіонова, Я.В. Гільова, Н.В. Титаренко

Література

  1. Alfonso F, Bastante T, Antuña P, de la Cuerda F, Cuesta J, García-Guimaraes M, Rivero F. Coronary lithoplasty for the treatment of undilatable calcified de novo and in-stent restenosis lesions. JACC Cardiovasc Interv. 2019;12:497-9. doi: 10.1016/j.jcin.2018.12.025.
  2. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659-73. doi: 10.1016/j.jacc. 2014.02.545.
  3. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro  H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18(14):3964-72. doi: 10.1093/emboj/18.14.3964.
  4. Bagyura Z, Kiss L, Hirschberg K, Berta B, Széplaki G, Lux Á, Szelid Z, Soós P, Merkely B. Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent. Dis Markers. 2017;2017:9548-612. doi: 10.1155/2017/9548612.
  5. Berenguer A, Mainar V, Bordes P, Valencia J, Gomez S, Lozano T. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients. Am Heart J. 2005;150:536-42.
  6. Chan AW MD. Clinical Evaluation of Restenosis // Atherothrombosis and coronary artery disease / Fuster V, Topol EJ, Nabel EG, ed. Philadelphia: Lippincott Williams & Wilkins, 2004. P. 1415-41.
  7. Chen HJ, Mo N, Zhang YF, Su GZ, Wu HD, Pei F. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients. Int Heart J. 2018;59(1):161-9. doi: 10.1536/ihj.17-190.
  8. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151(6):1260-4. doi: 10.1016/j.ahj.2005.08.011.
  9. Cheng G, Chang FJ, Wang Y, You PH, Chen HC, Han WQ, Wang JW, Zhong NE, Min ZQ. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up. Med Sci Monit. 2019;25:240-7. doi: 10.12659/MSM.908692.
  10. Cho JY. Identification of Risk Factors Influencing In-Stent Restenosis with Acute Coronary Syndrome Presentation. Chonnam Med J. 2017; 53:203-21. doi: 10.4068/cmj.2017.53.3.203.
  11. Christen T, Verin V, Bochaton-Piallat M, Popowski Y, Ramaekers F, Debruyne P, Camenzind E, van Eys G, Gabbiani G. Mechanisms of neointima formation and remodeling in the porcine coronary artery. Circulation. 2001;103(6):882-8. doi: 10.1161/01.cir.103.6.882.
  12. Chung WS, Park CS, Seung KB, Kim PJ, Lee JM, Koo BK, Jang  YS, Yang JY, Yoon JH, Kim DI, Yoon YW, Park JS, Cho YH, Park SJ. The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol. 2008;125:325-31. doi: 10.1016/j.ijcard.2007.02.033.
  13. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897-907. doi: 10.1016/j.jacc.2010.07.028.
  14. Ding M, Rzucidlo EM, Davey JC, Xie Y, Liu R, Jin Y, Stavola L, Martin KA. Adiponectin in the heart and vascular system. Vitam Horm. 2012;90:289-319. doi: 10.1016/B978-0-12-398313-8.00011-7.
  15. Donners MM, Daemen MJ, Cleutjens KB, Heeneman S. Inflammation and restenosis: implications for therapy. Ann Med. 2003;35(7):523-31. doi: 10.1080/07853890310014876.
  16. Fujino A, Mintz GS, Matsumura M, Lee T, Kim SY, Hoshino M, Usui E, Yonetsu T, Haag ES, Shlofmitz RA, Kakuta T, Maehara  A. A new optical coherence tomography-based calcium scoring system to predict stent underexpansion. EuroIntervention. 2018;13:e2182-9. doi: 10.4244/EIJ-D-17-00962.
  17. Garcia R, Bouleti C, Sirol M, Logeart D, Monnot C, Ardidie-Robouant C, Caligiuri G, Mercadier JJ, Germain S. VEGF-A plasma levels are associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2019;291:19-24. doi: 10.1016/j.ijcard.2019.02.067.
  18. Gori T. Endothelial Function: A Short Guide for the Interventional Cardiologist. Int J Mol Sci. 2018;19(12):3838. doi: 10.3390/ijms19123838.
  19. Gori T. Vascular Wall Reactions to Coronary Stents – Clinical Implications for Stent Failure. Life. 2021;11:63. doi: 10.3390/life11010063.
  20. Goto K, Zhao Z, Matsumura M, Dohi T, Kobayashi N, Kirtane AJ, Rabbani LE, Collins MB, Parikh MA, Kodali SK, Leon MB, Moses JW, Mintz GS, Maehara A. Mechanisms and patterns of intravascular ultrasound in-stent restenosis among bare metal stents and first- and secondgeneration drug-eluting stents. Am J Cardiol. 2015;116:1351-7. doi: 10.1016/j.amjcard.2015.07.058.
  21. Hutter R, Carrick FE, Valdiviezo C, Wolinsky C, Rudge JS, Wiegand SJ, Fuster V, Badimon JJ, Sauter BV. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. Circulation. 2004;110(16):2430-5. doi: 10.1161/01.CIR.0000145120.37891.8A.
  22. Jiang H, Zhang H, Yang Y, Yang X. Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case-control study in China. BMJ open. 2020;10(11):e039405. doi:10.1136/bmjopen-2020-039405.
  23. Jinnouchi H, Kuramitsu S, Shinozaki T, Tomoi Y, Hiromasa T, Kobayashi Y, Domei T, Soga Y, Hyodo M, Shirai S, Ando K. Difference of Tissue Characteristics Between Early and Late Restenosis After Second-Generation Drug-Eluting Stents Implantation – An Optical Coherence Tomography Study. Circulation. 2017;81(4):450-7. doi: 10.1253/circj.CJ-16-1069.
  24. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333-42. doi: 10.1016/j.jacc.2008.04.030.
  25. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113(19):2293-300. doi: 10.1161/CIRCULATIONAHA.105.601823.
  26. Katsaros KM, Kastl SP, Krychtiuk KA, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl WS. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. EuroIntervention. 2014;10(2):224-30. doi: 10.4244/EIJV10I2A36.
  27. Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M, Bogdanski P, Cieslewicz A, Jablecka A. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. Eur Rev Med Pharmacol Sci. 2014;18(15):2169-75.
  28. Keavney B. Outcome following percutaneous coronary intervention: not, so far, in our genes. Heart. 2003;89(3):247-8. doi: 10.1136/heart.89.3.247.
  29. Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther. 2011;29:190–8. doi: 10.1111/j.1755-5922.2010.00155.x
  30. Koch W, Böttiger C, Mehilli J, Neumann FJ, Schömig A, Kastrati A. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am. J. Cardiol. 2001;88(10):1120-4. doi: 10.1016/S0002-9149(01)02045-8.
  31. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation. 2003;108:257-60. doi: 10.1161/01.CIR.0000083366.33686.11
  32. Li HC, Cao GQ, Liu CZ, Tang MM, Zhang XQ. Gene polymorphism of adiponectin in restenosis after coronary stenting. Eur Rev Med Pharmacol Sci. 2019;23(3 Suppl):287-93. doi: 10.26355/eurrev_201908_18659.
  33. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004;109(4):476-80. doi: 10.1161/01.CIR.0000109693.64957.20.
  34. Nakamura D, Yasumura K, Nakamura H, Matsuhiro Y, Yasumoto K, Tanaka A, Matsunaga-Lee Y, Yano M, Yamato  M, Egami Y, Shutta R, Sakata Y, Tanouchi J, Nishino M. Different Neoatherosclerosis Patterns in Drug-Eluting- and Bare-Metal Stent Restenosis – Optical Coherence Tomography Study. Circulation. 2019;83(2):313-9. doi: 10.1253/circj.CJ-18-0701.
  35. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi  Y, Yoshiyama M, Takeuchi K, Yoshikawa J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004;90(5):528-33. doi: 10.1136/hrt.2003.011114.
  36. Ohtani K, Egashira K, Hiasa K, Zhao Q, Kitamoto S, Ishibashi  M, Usui M, Inoue S, Yonemitsu Y, Sueishi K, Sata M, Shibuya M, Sunagawa K. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation. 2004;110(16):2444-52. doi: 10.1161/01.CIR.0000145123.85083.66.
  37. Osadnik T, Strzelczyk JK, Reguła R, Bujak K, Fronczek M, Gonera M, Gawlita M, Wasilewski J, Lekston A, Kurek A, Gierlotka M, Trzeciak P, Hawranek M, Ostrowska Z, Wiczkowski A, Poloński L, Gąsior M. The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent. PLoS One. 2016;11(3):e0150500. doi: 10.1371/journal.pone.0150500.
  38. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara  D, et al. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;101:1-7.
  39. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Genereux P, Branzi A, Stone GW. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol. 2013;62(21):1915-21. doi: 10.1016/j.jacc.2013.08.725.
  40. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol. 2005;524(1–3):19-29. doi: 10.1016/j.ejphar.2005.09.042.
  41. Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, van Vlijmen BJ, Rosendaal FR, Zwinderman AH, Doevendans PA, Waltenberger J, de Winter RJ, Tio RA, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost. 2007;98(6):1323-8.
  42. Schnorbus B, Daiber A, Jurk K, Warnke S, König J, Krahn U, Lackner K, Munzel T, Gori T. Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, blinded, parallel study. Eur Heart J. 2020;41(33):3144-52. doi:10.1093/eurheartj/ehz917.
  43. Shlofmitz E, Iantorno M, Waksman R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Re­­­view. Circ Cardiovasc Interv. 2019;12(8):e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023.
  44. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O’Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215-23. doi: 10.1001/jama.294.10.1215.
  45. Tiyerili V, Camara B, Becher MU, Schrickel JW, Lütjohann D, Mollenhauer M, Baldus S, Nickenig G, Andrié RP. Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. Int J Cardiol. 2016;204:29-36. doi: 10.1016/j.ijcard.2015.11.128.
  46. Тsigkas GG, Karantalis V, Hahalis G, Alexopoulos D. Stent restenosis, pathophysiology and treatment options: a 2010 update. Hellenic J Cardiol. 2011;52(2):149-57.
  47. Verschuren JJ, Trompet S, Postmus I, Sampietro ML, Heij­­­mans BT, Houwing-Duistermaat JJ, Slagboom PE, Jukema  JW. Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. PLoS One. 2012;7(8):e42401. doi: 10.1371/journal.pone.0042401.
  48. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701-5. doi: 10.1161/01.CIR.0000116202.41966.D4.
  49. Xu X, Pandit RU, Han L, Li Y, Guo X. Remnant Lipopro­­­­tein Cholesterol Independently Associates With In-Stent Restenosis After Drug-Eluting Stenting for Coro­­­­nary Artery Disease. Angiology. 2019;70(9):853-9. doi: 10.1177/0003319719854296.
  50. Yang J, Zeng Y, Zhang C, Chen YX, Yang Z, Li Y, Leng X, Kong D, Wei XQ, Sun HF, Song CX. The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. Biomaterials. 2013;34(6):1635-43. doi: 10.1016/j.biomaterials.2012.11.006.
  51. Zeng WP, Zhang R, Li R, Luo JF, Hu XF. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent. PLoS One. 2017;12(1):e0170964. doi: 10.1371/journal.pone.0170964.
  52. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between mye­­loperoxidase levels and risk of coronary artery disease. JAMA. 2001;286(17):2136-42. doi: 10.1001/jama.286.17.2136.
  53. Zhu X, Chen Y, Xiang L, You T, Jiao Y, Xu W, Chen J. The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis. Medicine (Baltimore). 2018;97(27):e10679. doi: 10.1097/MD.0000000000010679.
[PDF] [Зміст журналу]  

 

 

Аналіз ранніх кардіальних ускладнень після аортокоронарного шунтування при використанні двох різних схем анестезіологічного забезпечення

С.Р. Маруняк, О.А. Лоскутов, І.Р. Малиш

Література

  1. Beloeil H. Opioid-free anesthesia. Best Pract Res Clin Anaesthesiol. 2019;33(3):353-60. doi: 10.1016/j.bpa.2019.09.002. Epub 2019 Sep 26. PMID: 31785720.
  2. Bridgewater B, Keogh B. Sixth national adult cardiac surgical database report 2008: improving outcomes for patients. Oxfordshire UK: Dendrite Clinical Systems, 2009.
  3. Chia PA, Cannesson M, Bui CCM. Opioid free anesthesia: feasible? Curr Opin Anaesthesiol. 2020;33(4):512-7. doi: 10.1097/ACO.0000000000000878. PMID: 32530891; PMCID: PMC7502015.
  4. Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia – when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019;393(10180):1558-68. doi: 10.1016/S0140-6736(19)30430-1. PMID: 30983591.
  5. Dayer LE, Painter JT, McCain K, King J, Cullen J, Foster HR. A recent history of opioid use in the US: Three decades of change. Subst Use Misuse. 2019;54(2):331-9. doi: 10.1080/10826084.2018.1517175. Epub 2018 Dec 21. PMID: 30572776.
  6. Ding W, Ji Q, ​​Shi Y, Ma R. Predictors of low cardiac output syndrome after isolated coronary artery bypass grafting. Int Heart J. 2015;56(2):144-9. doi: 10.1536/ihj.14-231.
  7. Forget P. Opioid-free anesthesia. Why and how? A contextual analysis. Anaesth Crit Care Pain Med. 2019;38(2):169-72. doi: 10.1016/j.accpm.2018.05.002. Epub 2018 Sep 13. PMID: 29775728.
  8. Greco M, Landoni G, Biondi-Zoccai G, et al. Remifentanil in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2012;26(1):110-6. doi: 10.1053/j.jvca.2011.05.007. Epub 2011 Aug 5. PMID: 21820920.
  9. Landoni G, Rodseth RN, Santini F, et al. Randomized evidence for reduction of perioperative mortality. J Cardiothorac Vasc Anesth. 2012;26(5):764-72. doi: 10.1053 / j.jvca.2012.04.018. Epub 2012 Jun 20. PMID: 22726656.
  10. Loskutov O, Maruniak S, Dryzhyna O, Malysh I, Kolesnykov V, Korotchuk N. Influence of low-opioid anesthesia in cardiac surgery on the dynamics of pro-inflammatory interleukin-6. Kardiochir Torakochirurgia Pol. 2020;17(1):39-43. doi: 10.5114/kitp.2020.94190. Epub 2020 Apr 7. PMID: 32728362; PMCID: PMC7379208.
  11. Lowenstein E. Morphine «anesthesia» – a perspective. Anesthesiology. 1971;35(6):563-5. doi: 10.1097/00000542-197112000-00001. PMID: 5124736.
  12. Rocha EAV. Fifty years of coronary artery bypass graft surgery. Braz J Cardiovasc Surg. 2017;32(4):II-III. doi: 10.21470/1678-9741-2017-0104. PMID: 28977193; PMCID: PMC5613722.
  13. Rong LQ, Kamel MK, Rahouma M, et al. High-dose versus low-dose opioid anesthesia in adult cardiac surgery: A meta-analysis. J Clin Anesth. 2019;57:57-62. doi: 10.1016/j.jclinane.2019.03.009. Epub 2019 Mar 11. PMID: 30870677.
  14. Severino P, D’Amato A, Pucci M, et al. Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction. Int J Mol Sci. 2020;21(21):8118. doi: 10.3390 / ijms21218118. PMID: 33143256; PMCID: PMC7663258.
  15. Wong WT, Lai VK, Chee YE, Lee A. Fast-track cardiac care for adult cardiac surgical patients. Cochrane Database Syst Rev. 2016;9(9);CD003587. doi: 10.1002/14651858.CD003587.pub3. PMID: 27616189; PMCID: PMC6457798.
[PDF] [Зміст журналу]  

 

 

Ставлення пацієнтів кардіохірургічного профілю до проблем донорства і трансплантації органів

Г.І. Ковтун

Література

  1. Dunayevsʹka L.H. Transplantatsiya orhaniv i tkanyn lyudyny: pravovyy ta kryminalistychnyy analiz / Dunayevsʹka L.H., Lushpiyenko V. M. // Visnyk natsionalʹnoho tekhnichnoho universytetu Ukrayiny „Kyyivsʹkyy politekhnichnyy instytut”. Politolohiya Sotsiolohiya. Pravo: Zb. nauk. pratsʹ. – K.: NTUU „KPI”, 2012. – №3 (15). – S. 206-209.

  2. Rozvytok orhannoyi transplantatsiyi zalezhytʹ vid mozhlyvostey diahnostyky smerti mozku. 2019. URL: https://www.vz.kiev.ua/rozvytok-organnoyi-transplantatsiyi-zalezhyt-vid-mohlyvostej-diagnostyky-smerti-mozku/
  3. Alsynbayeva E. M. Tsyvilʹno-pravove rehulyuvannya nadannya medychnykh posluh z transplantatsiyi orhaniv ta tkanyn lyudyny: dys. kand. yur. nauk: 12.00.03 – M., 2013. – 164 s
  4. Bahnenko S.F. Analiz prychyn defitsytu donoriv orhaniv ta osnovni napryamy yoho podolannya / S.F. Bahnenko [ta in] // Transplantolohiya. – 2011. – №2-3. – S. 10–22.
  5. Mikhelʹ D. Rozvytok vysokotekhnolohichnoyi okhorony zdorov’ya v Yevropi: donorstvo ta transplantatsiya orhaniv / Yevropeysʹka bezpeka: podiyi, otsinky, tsiny, prohnozy 2020 Vypusk 56 (72) stor.2-11. URL. https:// hromadske.ua/ru/posts/s-nachala-2021-goda-v-ukraine-proveli-48-operacij-po-transplantacii-organo
  6. Zakon Ukrayiny "Pro zastosuvannya transplantatsiyi anatomichnykh materialiv lyudyny" vid 17 travnya 2018 roku №2427-VIII // URL: https://zakon.rada. gov. ua/laws/show/2427-19#Text
  7. Zakon Ukrayiny "Pro vnesennya zmin do deyakykh zakonodavchykh aktiv Ukrayiny shchodo zastosuvannya transplantatsiyi anatomichnykh materialiv lyudyny vid 28 lyutoho 2019 roku №2694-VIII // URL: https: base. spinform.ru/show_ doc. fwx?rgn=115055
  8. Zakon Ukrayiny «Pro vnesennya zmin do deyakykh zakoniv Ukrayiny, shcho rehulyuyutʹ pytannya transplantatsiyi anatomichnykh materialiv lyudyni»: vid 16.12.2021 № 1967-IX // URL: https: zakon.rada.gov. ua/laws/ show/1967-20#Text.
[PDF] [Зміст журналу]  

 

 

Клінічний випадок хірургічного лікування тромбоемболії легеневої артерії

С.О. Шелудько, А.С. Бацюн, Є.В. Прокопенко, Т.М. Симоненко, М.О. Яременко, С.Ю. Марікуца

Література

  1. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, Nаgako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6. Epub 2011 Jun 22. PMID: 21703676.
  2. Barrios D, Morillo R, Yusen RD, Jiménez D. Pulmonary embolism severity assessment and prognostication. Thromb Res. 2018;163:246-51. doi: 10.1016/j.thromres.2017.09.007. Epub 2017 Sep 8. PMID: 28911787.
  3. Donzé J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, Cornuz J, Meyer G, Perrier A, Righini M, Aujesky D. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost. 2008;100(5):943-8. doi: 10.1160/th08-05-0285. PMID: 18989542.
  4. Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. Clinicoecon Outcomes Res. 2015;7:451-62. doi: 10.2147/CEOR.S85635. PMID: 26355805; PMCID: PMC4559246.
  5. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370-2. doi: 10.1161/ATVBAHA.108.162545. PMID: 18296591; PMCID: PMC2873781.
  6. Jolly M, Phillips J. Pulmonary Embolism: current role of catheter treatment options and operative thrombectomy. Surg Clin North Am. 2018;98(2):279-92. doi: 10.1016/j.suc.2017.11.009. PMID: 29502772.
  7. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, Ten Cate-Hoek AJ, Elalamy I, Enzmann   FK, Geroulakos G, Gottsäter A, Hunt BJ, Mansilha  A, Nicolaides AN, Sandset PM, Stansby G, Esvs Guidelines Committee, de Borst GJ, Bastos Gonçalves F, Chakfé N, Hinchliffe R, Kolh P, Koncar I, Lindholt JS, Tulamo R, Twine CP, Vermassen F, Wanhainen A, Document Reviewers, De Maeseneer MG, Comerota AJ, Gloviczki P, Kruip MJHA, Monreal M, Prandoni P, Vega de Ceniga M. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9-82. doi: 10.1016/j.ejvs.2020.09.023. Epub 2020 Dec 15. PMID: 33334670.
  8. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing  GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi: 10.1093/eurheartj/ehz405. PMID: 31504429.
  9. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-8. doi: 10.1161/01.CIR.0000078468.11849.66. PMID: 12814979.
[PDF] [Зміст журналу]  

 

 

Інфіковані міксоми серця: стан проблеми та випадок з кардіохірургічної практики

Р.М. Вітовський, В.В. Ісаєнко, Т.І. Дєдкова, О.А. Піщурін, В.П. Захарова, А.Д. Кіпіоро

Література

  1. Bruce C.J. Cardiac tumours: Diagnosis and management.// Heart 2011;97:151‑60.  DOI: 10.1136/hrt.2009.186320  
  2. Bakaeen FG, Jaroszewski DE, Rice DC, Walsh GL, Vaporciyan AA, Swisher S, Benjamin R, Blackmon S, Reardon MJ. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J Thorac Cardiovasc Surg. 2009;137(6):1454-60. DOI: 10.1016/j.jtcvs.2008.11.026.
  3. Bruce CJ. Cardiac tumours: Diagnosis and management. Heart. 2011;97:151-60. DOI: 10.1136/hrt.2009.186320.
  4. Chia-Te Liao, Jhih-Yen Shih, Zhih-Cherng Chen, Jinn-Ming Chang, Wan-Ling Miriam Wu, Wen-Shiann Wu. Management of a primary cardiac neoplasm with tumor blush by a stent graft. Acta Cardiol Sin. 2015;31:164-7. DOI: 10.6515/acs20140502a.
  5. Cianciulli TF, Cozzarin A, Soumoulou JB, et al. Twenty years of clinical experience with cardiac myxomas: diagnosis, treatment, and follow up. J Cardiovasc Imaging. 2019;27(1):37-47. DOI: 10.4250/jcvi.2019.27.e7.
  6. Khanal S, Pruthvi CR, Kanabar K, Bootla D, Prasad K. Left atrial tumor, complete heart block, and triple-vessel coronary artery disease: a very rare case report. J Clin Prevent Cardiol. 2019;8(3):139-41. DOI: 10.4103/JCPC.JCPC-21-19.
  7. Knyshov GV, Vitovsky RM, Zaharova VP. Tumors of the heart. Presa Ukrainy, 2005. 256 p. (in Russ.).
  8. Leja MJ, Shah DJ, Reardon MJ. Primary cardiac tumors.Tex Heart Inst J. 2011;38:261-2. PMCID: PMC3113129PMID: 21720466.
  9. Miller DV, Revelo M. Diagnostic Pathology: Cardiovascular. 2th ed. Elsiver, 2018. 468 р. ISBN: 978-0-323-59560-5.
  10. Molnar A, Muresan I, Trifan C, Pop D, Sacui D. Surgical outcomes in native valve infectious endocarditis: the experience of the Cardiovascular Surgery Department – Cluj-Napoca Heart Institute. Clujul Med. 2015;88(3):338-42.doi: 10.15386/cjmed-482. 
  11. Patel K, Rahul K, Tarsaria M, Malhotra A. Left atrial myxoma following coronary artery bypass grafting with patient coronary arterial grafts: a rarity. Braz J Cardiovasc Surg. 2017;32(3):228-30. DOI: 10.21470/1678-9741-2016-0080.
  12. Revankar SG, Clark RA. Infected cardiac myxoma.Case report and literature review. Medicine (Baltimore). 1998;77(5):337-44. DOI: 10.1097/00005792-199809000-00003.
  13. Shi-Min Yuan, Song-Li Yan, Ning Wu. Unusual aspects of cardiac myxoma. Anatol J Cardiol. 2017;17(3):241-7.DOI: 10.14744/AnatolJCardiol.2017.7557.
  14. Van Trigt P III, Sabiston DC Jr. Tumors of the heart // Eds. Sabiston DC Jr, Spencer FC. Surgery of the Chest. Vol. 2,6th ed. Philadelphia: WB Saunders, 1995. P. 2069-88.
[PDF] [Зміст журналу]  

 

 

Роль катетеризації серця у прийнятті рішення про хірургічне лікування симптоматичної гіпертрофічної кардіоміопатії

Б.М. Тодуров, М.Б. Тодуров, А.В. Хохлов, А.А. Кривошея, Л.Р. Стецюк, К.С. Бойко, М.В. Стан, В.С. Миронова

Література

  1. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.
  2. Bishu K, Coylewright M, Nishimura R. The role of hemodynamic catheterization in the evaluation of hypertrophic obstructive cardiomyopathy: A case series. Catheter Cardiovasc Interv. 2015;86(5):903-12. doi: 10.1002/ccd.25856.
  3. Caravita S, Baratto C, Perego GB, Cecchi F, Crotti L, Parati G. Invasive Hemodynamics of Hypertrophic Cardiomyopathy Exercise Versus Isoprotereno. Circulation: Heart Failure. 2020;13:e007000. doi:10.1161/CIRCHEARTFAILURE.120. l007000.
  4. El-Sabawi B, Nishimura RA, Guerrero ME, Rihal CS, Eleid MF. Alcohol septal ablation in patients with concomitant hypertrophic cardiomyopathy and aortic valvular stenosis. Catheter Cardiovasc Interv. 2020;95(4):830-7. doi:10.1002/ccd.28442.
  5. Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JCIN. 2011;4:704-9.
  6. Jain R, Osranek M, Jan MF, Kalvin LR, Olet S, Allaqaband SQ, Jahangir A, Khandheria BK, Tajik AJ. Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: an observational study. Eur Heart J Cardiovasc Imaging. 2018;19(10):1126-33. doi:10.1093/ehjci/jex215.
  7. Kumar S, Van Ness G, Bender A, Yadava M, Minnier J, Ravi S, McGrath L, Song HK, Heitner SB. Standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Amer Soc Echocardiogr. 2018;31(7):791-8. doi:10.1016/j.echo.2018.01.022.
  8. Lapenna E, Nisi T, Carino D, Bargagna M, Ruggeri S, Zancanaro E, Del Forno B, Schiavi D, Agricola E, Castiglioni A, Alfieri O, De Bonis M. Hypertrophic cardiomyopathy with moderate septal thickness and mitral regurgitation: long-term surgical results. Eur J Cardiothorac Surg. 2021;60(2):244-51. doi:10.1093/ejcts/ezab097.
  9. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Garcia-Pavia P, Limongelli G, Pavlou M, Elliott PM, Hypertrophic Cardiomyopathy Outcomes investigators. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European Population. JAMA Cardiol. 2020;5(1):73-80. doi: 10.1001/jamacardio.2019.4534.
  10. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and evaluation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79(4):372-89. doi: 10.1016/j.jacc.2021.12.002.
  11. Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization caboratory of the 21st century. Circulation. 2012;125:2138-50. doi:10.1161/CIRCULATIONAHA.111.060319.
  12. Sharkawi MA, Azemi T, Duncan B, Sadiq I. Subaortic Membrane and hypertrophic obstructive cardiomyopathy in the cardiac catheterization lab. ACC Cardiovasc Interv. 2017;10(15):e143-5. doi: 10.1016/j.jcin.2017.05.054.
  13. Wang Y, Zhang YM, Dong JG, Cheng LJ, Jiang GH, Zheng JW, Yu WZ. A case report and analysis of hypertrophic obstructive cardiomyopathy causing an illusion of aortic stenosis. Medicine (Baltimore). 2018;97(50):e13711. doi: 10.1097/MD.0000000000013711.
[PDF] [Зміст журналу]  

 

 

Хірургічне лікування гігантської аневризми дуги аорти в дівчинки віком 13 років

В.Ю. Вашкеба, В.Г. Карпенко, О.В. Зеленчук, В.В. Сакалов, В.Б. Демянчук

Література

  1. Cameron D. Surgery for congenital diseases of the aorta. J Thorac Cardiovasc Surg. 2015;149:S14-7.
  2. Caputo M, Chivasso P, Skerritt C, Ofoe V. Unusual Presenta­­­tion of Large Aortic Arch Aneurysms Associated with Aortic Coarctation in a 15-Year-Old Girl. Available at https://www.ctsnet.org/article/unusual-presentation-large-aortic-arch-aneurysms-associated-aortic-coarctation-15-year-old. Accessed February 3, 2015.
  3. Ramayya AS, Coelho R, Sivakumar K, Radhakrishan S. Repair of tetralogy of Fallot with ascending and proximal aortic arch aneurysm: case report. J Card Surg. 2011;26(3):328-30.
[PDF] [Зміст журналу]  

 

 

Реваскуляризація нирок при реноваскулярній хворобі: наукова заява Американської асоціації серця

V. Bhalla, S.C. Textor, J.A. Beckman, A.I. Casanegra, C.J. Cooper, E.S.H. Kim, J.M. Luther, S. Misra, G.S. Oderich

Література

 

Повний список літератури

 

[PDF] [Зміст журналу]  

Crossref Member Badge

Анонс

ФУНКЦІОНАЛЬНА ДІАГНОСТИКА СЕРЦЕВО-СУДИННИХ ХВОРОБ

ХII щорічна науково-практична конференція
14–15 березня 2024 року

ПРОГРАМА КОНФЕРЕНЦІЇ

____________________________

 

Партнери сайту

Berlin-Chemie Menarini

Цибор